Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | CREBBP | Q92793 | 10/20 | 0.47 |
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
| ▸ | MET | P08581 | 3/20 | 0.46 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.45 |
| ▸ | EP300 | Q09472 | 9/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4713062 | 0.84 | MAPK1 (0.67) | MAPK1CREBBPBRD4METBAZ2B | |
| SCHEMBL10817751 | 0.83 | MAPK1 (0.71) | MAPK1CREBBPBRD4METBAZ2B | |
| SCHEMBL2982055 | 0.81 | MAPK1 (0.78) | MAPK1CREBBPBRD4METBAZ2B | |
| SCHEMBL7093107 | 0.79 | MAPK1 (0.65) | MAPK1CREBBPBRD4METBAZ2B | |
| SCHEMBL10817743 | 0.77 | MAPK1 (0.80) | MAPK1CREBBPBRD4BAZ2BEP300 | |
| SCHEMBL10805635 | 0.76 | MAPK1 (1.00) | MAPK1CREBBPBRD4BAZ2BEP300 | |
| SCHEMBL2979198 | 0.76 | MAPK1 (0.78) | MAPK1CREBBPBRD4BAZ2BEP300 | |
| SCHEMBL2977735 | 0.76 | MAPK1 (0.78) | MAPK1CREBBPBRD4METEP300 | |
| SCHEMBL10818694 | 0.76 | MAPK1 (0.77) | MAPK1CREBBPBRD4BAZ2BEP300 | |
| SCHEMBL14791448 | 0.76 | MAPK1 (0.66) | MAPK1CREBBPBRD4BAZ2BEP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772236-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7589202-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-20080300255-A1 | Substituted pyrazoles | BEAVERS MARY PAT | 2008-12-04 | — | — | US | disclosed |
| US-20080293732-A1 | Substituted pyrazoles | BEAVERS MARY PAT | 2008-11-27 | — | — | US | disclosed |
| US-7452890-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7429591-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7417046-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-7393850-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7388011-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-7332494-B2 | Method for treating allergies using substituted pyrazoles | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-02-19 | — | — | US | disclosed |
| US-20070004738-A1 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004754-A1 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2007-01-04 | — | — | US | disclosed |
| EP-1315491-B1 | USE OF SUBSTITUTED PYRAZOLES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF ALLERGIES | ORTHO MCNEIL PHARM INC (US) | 2006-08-09 | — | — | EP | disclosed |
| EP-1315491-A2 | METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-06-04 | — | — | EP | disclosed |
| EP-1309591-A2 | SUBSTITUTED PYRAZOLES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20030073672-A1 | Method for treating allergies using substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-04-17 | — | — | US | disclosed |
| US-20030069240-A1 | Method for treating allergies using substituted pyrazoles | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-04-10 | — | — | US | disclosed |
| US-20020040020-A1 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-04-04 | — | — | US | disclosed |
| WO-2002020012-A2 | METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002014314-A2 | SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293732-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSB | MAPK1 4519/4885CREBBP 2922/4885BRD4 605/4885 |
| US-20080300255-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSB | MAPK1 4519/4885CREBBP 2922/4885BRD4 605/4885 |
| US-20070004738-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSB | MAPK1 4519/4885CREBBP 2922/4885BRD4 605/4885 |
| US-20030069240-A1 | Method for treating allergies using substituted pyrazoles | TSLP, IL33, HRH2 | MAPK1 4370/4885CREBBP 1005/4885BRD4 140/4885 |
| US-20030073672-A1 | Method for treating allergies using substituted pyrazoles | TSLP, IL33, HRH2 | MAPK1 4370/4885CREBBP 1005/4885BRD4 140/4885 |
| US-20070004754-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSB | MAPK1 4519/4885CREBBP 2922/4885BRD4 605/4885 |
| US-20020040020-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSV | MAPK1 4426/4885CREBBP 3211/4885BRD4 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.